Approval of unaudited financial results for the half year ended 30th September 2025, together with the Limited Review Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shanmuga Hospital's board approved its unaudited H1 FY26 results (period ended 30 Sept 2025) along with an unqualified limited review report from auditors PPN and Company. Revenue from operations came in at ₹2,462.07 lakhs, almost flat versus ₹2,462.18 lakhs in H1 FY25. Total income was ₹2,472.01 lakhs vs ₹2,482.81 lakhs. Profit before tax slipped to ₹270.33 lakhs from ₹323.60 lakhs, and PAT fell to ₹201.13 lakhs from ₹239.29 lakhs, with EPS at ₹1.48 versus ₹2.44. The company fully utilised its IPO proceeds of ₹2,061.72 lakhs during the half year, driving a sharp rise in property, plant and equipment to ₹3,762.57 lakhs (from ₹2,242.71 lakhs). Operating cash flow swung to a positive ₹2,012.58 lakhs from a negative ₹1,263.72 lakhs in FY25, supported by IPO-funded working capital movement. Depreciation surged 62% YoY due to newly commissioned assets.
Flat revenue and a 16% drop in PAT, combined with sharply higher depreciation from IPO-funded capex, may pressure near-term profitability and investor sentiment, though the hospital is clearly in an expansion phase with full IPO deployment and a healthy operating cash turnaround.